Pegylated Liposomal Doxorubicin in Vindesine-Based and Bortezomib-Based Regimens for Patients With Newly Diagnosed Multiple Myeloma: A Retrospective Study of Efficacy and Safety

PURPOSE: Although pegylated liposomal doxorubicin (PLD) has been approved in combination with bortezomib for relapsed/refractory multiple myeloma (MM), the antitumor efficacy and tolerability of PLD in different regimens for patients with newly diagnosed MM (NDMM) have not been fully defined. METHOD...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Front Oncol
Main Authors: Zhai, Yujia, Yuan, Dai, Ge, Xueling, Hu, Shunfeng, Li, Peipei, Fang, Xiaosheng, Li, Ying, Zhou, Xiangxiang, Wang, Xin
Format: Artigo
Sprog:Inglês
Udgivet: Frontiers Media S.A. 2021
Fag:
Oncology
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8030239/
https://ncbi.nlm.nih.gov/pubmed/33842312
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.597453
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker